Deferiprone

Thalassemia

Mahidol UniversitySmall moleculeN/ADormant

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 89/ 100

Competitive context

22 Active assets in the Thalassemia cohort.

Asset / Sponsor	Phase	Rating
Deferasirox Novartis Pharmaceuticals	Phase 4	BBB
Fludarabine Memorial Sloan Kettering Cancer Center	Phase 2/3	BB
Hydroxyurea Riphah International University	Phase 4	BB
Ppsv23 Fakultas Kedokteran Universitas Indonesia	Phase 4	BB
Etavopivat Novo Nordisk A/S	Phase 3	BB

View all 50 →

Same molecule, other indications

Deferiprone is also rated in:

beta-thalassemia majorDormant

BBB

Indicative ·

77 / 100

iron metabolism diseaseDormant

BBB

Indicative ·

73 / 100

hemosiderosisDormant

BB

Indicative ·

71 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.